This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Insulin Glargine First Line vs Metformin in Type 2 Diabetic Subjects (GLORY)

This study has been completed.
Information provided by (Responsible Party):
GWT-TUD GmbH Identifier:
First received: March 6, 2009
Last updated: January 10, 2012
Last verified: January 2012
Comparison of efficacy and safety of glargine insulin and metformin as first line drug of patients insufficiently treated with lifestyle intervention. So far treatment also algorithm with lifestyle and metformin has not been evaluated in patients with type 2 diabetes and HbA1C greater or equal 7 % and lower than 8.1%.Besides HbA1C postprandial glucose excursion and glycemic variability as determinants of oxidative stress will be measured by continuous glucose measurement(CGM). Further more CGM will reveal risk of hypoglycemia at night. As secondary objectives effect on endothelial function, renal function and biomarkers of low great inflammation will be evaluated. So far only scarce information on face to face comparison in ealy diabetes exists.

Condition Intervention Phase
Type 2 Diabetes Drug: Metformin Drug: Insulin glargine Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparative Investigation of Efficacy and Safety of Insulin Glargine Versus Metformin as First Line Drug in Treatment of Early Type 2 Diabetes

Resource links provided by NLM:

Further study details as provided by GWT-TUD GmbH:

Primary Outcome Measures:
  • Area under the curve (AUC) after a testmeal measured CGM. [ Time Frame: baseline and visit 8 ]

Secondary Outcome Measures:
  • HbA1C, glycemic variability, glycemic load, insulin secretion after testmeal, free fatty acids, biomarkers of low grade inflammation, endothelial dysfunction. [ Time Frame: baseline and visit 8 ]

Enrollment: 96
Study Start Date: March 2009
Study Completion Date: December 2011
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Metformin Drug: Metformin

Metformin is administered as coated tablet. Initial dose is 500 mg twice a day (morning and evening) during or after the meal. The first administration takes place on the evening of visit 1c. The duration of the therapy is 36 weeks until visit 8c.

Initial dose of 500 mg bid was increased after 4 weeks (visit 2) to 850 mg bid when the patient tolerated the initial dose. If the side effects were not tolerable, the initial dose was decreased to 500 mg once a day and where appropriate increased at a later visit.

After 8 weeks (visit 3) metformin dose was increased to 1000 mg bid when tolerated. If dose is not tolerated, it was decreased to the next lower dose.

Active Comparator: Insulin glargine Drug: Insulin glargine
Insulin glargine is given subcutaneously with an insulin-pen (SoloStar®). The dose was titrated to reach a fasting plasma glucose value of <5.6 mmol/l. Insulin glargine was given once a day in the evening before going to bed (bed-time injection). The first insulin injection takes place on the evening of visit 1c. The duration of the therapy is 36 weeks until visit 8c. All patients were trained in handling and storage of the insulin-pen.


Ages Eligible for Study:   35 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • early type 2 diabetes (lower than 5 years known)
  • male and female(35 to 75 years)
  • HbA1c 7 to 8 %, if drug naive and <= 8.5 with previous OAD intake
  • Informed consent

Exclusion Criteria:

  • any treatment more than one OAD at the same time
  • treatment with one OAD < 6 weeks time
  • insulin treatment
  • acute coronary syndrome < 6 months
  • severe liver disease
  • alcohol abuse or drug addiction
  • severe kidney disease
  • acute critical illness with renal impairment
  • i.v. application of iodine
  • ketoacidosis
  • acute or chronic illness witch may lead to hypoxia or cardial failure
  • allergy against one of the drugs
  • deficit in compliance or cooperation
  • pregnancy or breast feeding
  • women in fertile age without accepted contraceptive
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00857870

GWT -TUD, Center for Clinical Studies
Dresden, Germany, 01307
Sponsors and Collaborators
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: GWT-TUD GmbH Identifier: NCT00857870     History of Changes
Other Study ID Numbers: GWT-2008-1
Study First Received: March 6, 2009
Last Updated: January 10, 2012

Additional relevant MeSH terms:
Diabetes Mellitus, Type 2
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin, Globin Zinc
Insulin Glargine
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on August 22, 2017